Nov 15, 2021 / 01:30PM GMT
Gena Wang - Barclays Capital - Analyst
Thank you, everyone. Welcome to our next presenting company. It is my great pleasure to introduce our next presenting company, Editas Medicine. With us, we have Lisa Michaels, Chief Medical Officer; we also have Mark Shearman, Chief Scientific Officer, with us. Lisa, Mark do you want to give a quick overview on Editas? And then we can dive into the questions.
Lisa Michaels - Editas Medicine, Inc. - EVP and CMO
No, Gena. It's wonderful to have an opportunity to talk to you and with everyone else today. I am just letting you know, this is the end of my first full year at Editas, and it has been an exciting road so far to date. My real pleasure over the last year has been really getting the clinical programs moving forward and getting momentum in patient enrollment across all our various programs and portfolio.
Over the last year, some of the main achievements that we have gotten is the BRILLIANCE study in Leber's congenital amaurosis type 10, moving forward relatively aggressively and had the first time that Editas
Editas Medicine Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers